stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Return on equity
Kymera Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was −27.3%, down 1.5 percentage points from fiscal 2025 (−25.8%). Over the past ten years it has ranged from −52.2% (fiscal 2020) to 75.8% (fiscal 2019); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of −50.1% and in line with the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −25.8% | 10.60 |
| FY2024 | −36.4% | (3.17) |
| FY2023 | −33.2% | (0.61) |
| FY2022 | −32.6% | (5.64) |
| FY2021 | −27.0% | 25.21 |
| FY2020 | −52.2% | (127.96) |
| FY2019 | 75.8% | 36.34 |
| FY2018 | 39.5% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IBRX ImmunityBio, Inc. compare | 122.9% |
| TGTX TG Therapeutics, Inc. compare | 100.3% |
| TECH Bio-Techne Corp compare | 9.03% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.31% |
| KYMR Kymera Therapeutics, Inc. | −27.3% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| PCVX Vaxcyte, Inc. compare | −36.5% |
| SMMT Summit Therapeutics PLC compare | −192.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement